Phenylephrine IV Injection Recalled for Lack of Sterility Assurance
Central Admixture Pharmacy Services recalls phenylephrine IV bags nationwide because the manufacturer lacks validated sanitization data to ensure sterility. Healthcare providers should identify and quarantine affected inventory.
What this means for you
Real risk of harm even if no illness or injury has been reported yet. Stop using the product and follow the agency's guidance.
Our severity reasoning: FDA Class II recall with no reported illnesses or injuries. The hazard—lack of sterility assurance in an IV drug due to unvalidated sanitization cycles—poses a risk of serious infection or contamination, meeting the criteria for high-risk products where injury has not yet been reported.
Plain-English summary
Central Admixture Pharmacy Services, Inc. is recalling 340 bags of phenylephrine added to 0.9% sodium chloride IV solution (50 mg/250mL, 200mcg/mL) due to lack of sterility assurance. The FDA is conducting this Class II recall because the manufacturer lacks validation data to confirm that their sanitization cycles are effective in preventing contamination.
The affected product (Lot #36-260038, expiration 10/3/2023, NDC 72196-7039-1) was distributed nationwide. IV medications must be sterile to be safely administered to patients.
Healthcare providers and facilities should identify any remaining inventory of the affected lot. Patients who received doses from this product should consult their healthcare provider regarding appropriate follow-up.
The recalled product
- Product
- PHENYLephrine added to 0.9% sodium chloride 50 mg/250mL (200mcg/mL), IV Bag, Rx Only, Central Admixture Pharmacy Services, Inc., 2200 South 43rd Avenue, Phoenix, AZ 85043. NDC:72196-7039-1
- Manufacturer
- Central Admixture Pharmacy Services, Inc.
- Hazard
- sterility-failure
- contamination-risk
- infection-risk
Is your product affected?
Check your packaging against the codes below. If any of them match, the product is part of this recall.
Lot numbers (2)
- Lot# 36-260038
- Exp 10/3/2023.
Distribution
Distributed nationwide across the United States.
Related recalls
Same category
- CriticalWarfarin Tablets Recalled After Mix-Up Between 2.5 mg and 5 mg Strengths
FDA (Drugs) · 2026-07-21
- ModerateFDA Recalls Pred Mild Ophthalmic Suspension Due to Failed Stability Specifications
FDA (Drugs) · 2026-06-03
- ModerateNicotine Transdermal System Patches Recalled for Oxidative Impurity Specification Failure
FDA (Drugs) · 2026-06-03
- HighLiraglutide Injection Recalled Due to Particulate Matter in Cartridges
FDA (Drugs) · 2026-05-27
- LowPrimidone Tablets Recalled for Cross-Contamination with Acemetacin
FDA (Drugs) · 2026-05-27